Myriad Genetics
MYGN
$18.18
Share price
1.11%
Change (1 day)
-14.61%
Change (1 year)
Myriad Genetics (MYGN) - Total debt
Total debt on the balance sheet as of December 2023 : $0.15 B
According to Myriad Genetics's latest financial reports the company's total debt is $0.15 B. A company’s total debt is the sum of all current and non-current debts.
Myriad Genetics - Total debt on balance sheet (from 2016 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.15 B | 4.9% |
| 2022-12-31 | $0.14 B | 57.1% |
| 2021-12-31 | $92.3 M | |
| 2020-06-30 | $0.29 B | 26.25% |
| 2019-06-30 | $0.23 B | 2410.75% |
| 2018-06-30 | $9.3 M | -90.62% |
| 2017-06-30 | $99.1 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | $15.62 B | 10,174.82% | 🇺🇸 USA |
 Exact Sciences EXAS | $2.55 B | 1,579.64% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.09 B | 620.41% | 🇺🇸 USA |
 Biocept
BIOC | $11.59 M | -92.38% | 🇺🇸 USA |
 Bio-Rad Laboratories BIO | $1.40 B | 824.02% | 🇺🇸 USA |